Further, our assay could be used even in laboratories not equipped for sophisticated analyses, resulting in a faster and cheaper method than the Sanger method and ddPCR, allowing a decrease in the cost and time for advances in molecular investigation and to correctly characterize AML IDH2 mutated patients. This evidence concerns the gene IDH2 and acute myeloid leukemia.